Our results provide evidence that the anti-tumor effect of combined tankyrase and checkpoint inhibitor treatment against B16-F10 tumors is dependent on both IFNγ and CD8+ T cells and occurs, at least in part, through direct suppression of WNT/β-catenin signaling within the tumor cells. This evidence concerns the gene CD8A and neoplasm.